Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Comment by lscfaon Feb 19, 2024 2:07pm
120 Views
Post# 35887759

RE:RE:RE:RE:RE:Revenue forecast

RE:RE:RE:RE:RE:Revenue forecastAlternative view. The $21M revenue includes starter kits (serum, 0.5% cream, 0.2% cream) and reorders for maintenance (0.2% cream)



 

2025

Starter Kit

70% Reorder

Starter rev @ $300

Reorder rev @ $100/mo

Total Revenue

January

1,550

 

465,000

 

465,000

February

1,938

 

581,250

 

581,250

March

2,422

 

726,563

 

726,563

April

1,942

1085

582,703

108,500

691,203

May

2,428

1356

728,379

135,625

864,004

June

3,035

1695

910,474

169,531

1,080,005

July

4,553

1360

1,365,942

135,964

1,501,906

August

5,691

1700

1,707,428

169,955

1,877,383

September

7,114

2124

2,134,284

212,444

2,346,728

October

8,361

3187

2,508,361

318,720

2,827,080

November

10,452

3984

3,135,451

398,400

3,533,850

December

13,064

4980

3,919,313

498,000

4,417,313

 

62,550

21,471

18,765,147

2,147,139

20,912,285

 

<< Previous
Bullboard Posts
Next >>